Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504790 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00504790 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 39 participants.
The verdict
NCT00504790, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, first time in human study of GSK923295, in adult subjects with cancers that do not respond to standard therapy. This study will be conducted in two stages; a dose-escalation stage (Stage 1) and an expansion cohort stage (Stage 2).
Interventions
- DRUG GSK923295
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-06-25 |
| Est. Completion | 2012-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504790
The ClinicalTrials.gov registry entry for NCT00504790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK923295 is the first listed.
NCT00504790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504790 about?
NCT00504790 is a clinical study titled "Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer". This is a Phase I, open-label, first time in human study of GSK923295, in adult subjects with cancers that do not respond to standard therapy. This study will be conducted in two stages; a dose-escalation stage (Stage 1) and an expansion cohort stage (Stage 2).
What is the current status of trial NCT00504790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2007-06-25. Estimated completion is 2012-05-08.
What interventions are being tested in trial NCT00504790?
The interventions under investigation include: GSK923295 (DRUG).
Who is sponsoring clinical trial NCT00504790?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.